Provided by Tiger Trade Technology Pte. Ltd.

Insmed

97.06
-4.6850-4.60%
Volume:1.18M
Turnover:115.83M
Market Cap:21.20B
PE:-23.74
High:101.05
Open:100.66
Low:96.68
Close:101.74
52wk High:212.75
52wk Low:90.39
Shares:218.38M
Float Shares:216.82M
Volume Ratio:0.79
T/O Rate:0.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.0882
EPS(LYR):-6.4200
ROE:-87.22%
ROA:-22.17%
PB:27.98
PE(LYR):-15.12

Loading ...

Insmed Price Target Cut to $198.00/Share from $212.00 by Roth Capital

Dow Jones
·
Sep 16

Movement Alert|Insmed Falls 5.04% in Regular Trading, Trading at $119.99

Market Focus
·
Sep 15

Insmed price target lowered to $198 from $212 at Roth Capital

TIPRANKS
·
Sep 15

Roth MKM Remains a Buy on Insmed (INSM)

TIPRANKS
·
Sep 15

Analysts’ Opinions Are Mixed on These NA Stocks: SpaceX (SPCX), Insmed (INSM) and Exelixis (EXEL)

TIPRANKS
·
Sep 13

Insmed Reports Inducement Awards of 115,320 RSUs and Stock Options Priced at USD 121.82 Per Share

Reuters
·
Sep 04

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Sep 04

Is Insmed (INSM) Undervalued Following Japan Approval For BRINSUPRI?

Simply Wall St.
·
Sep 01

Movement Alert|Insmed Rises 5.87% in Pre-Market Trading, Core Drug Brinsupri Approved in Japan

Market Focus
·
Aug 28

RBC Capital Reaffirms Their Buy Rating on Insmed (INSM)

TIPRANKS
·
Aug 27

Insmed to Present at Cantor Fitzgerald Global Healthcare Conference

Reuters
·
Aug 26

U.S. Research Roundup-Masco, Sherwin-Williams, Vulcan Materials

Reuters
·
Aug 25

Insmed Stock Seen by Mizuho as Undervalued

Dow Jones
·
Aug 25

Insmed Earns Buy Rating as Brinsupri Japan Approval Drives Stronger Global Outlook and Price Target Raised to $195

TIPRANKS
·
Aug 25

Mizuho ups Insmed price target, says share weakness is unwarranted

TIPRANKS
·
Aug 25

Insmed's Lung Disease Drug Gets Approved in Japan

MT Newswires Live
·
Aug 24

Insmed Says Japan Health Ministry Approves Brinsupri for Non-Cystic Fibrosis Bronchiectasis

Reuters
·
Aug 24

Brinsupri® (Brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients with Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

THOMSON REUTERS
·
Aug 24

Insmed Director Melvin Sharoky, M.D. Sells 5,000 Shares for $637,650

Reuters
·
Aug 20

Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Insmed (INSM)

TIPRANKS
·
Aug 18